Both oncologists and cancer patients recognize the benefits of physical activity during treatment, but oncologists may feel ill-equipped to give recommendations on exercise, according to a new study.
Mark L. Fuerst
Adding selumetinib to docetaxel does not provide any significant benefit over docetaxel alone for patients previously treated for advanced KRAS-mutant non–small-cell lung cancer.
A noninvasive PET imaging method may serve as a useful predictive biomarker for responses to cancer immunotherapy, according to a new study.
Cytomegalovirus targeted vaccination plus high-dose chemotherapy with temozolomide can lead to long-term progression-free and overall survival in patients with newly diagnosed glioblastoma.
A nivolumab/ipilimumab combination significantly improved overall survival for advanced melanoma patients.
Young men who are overweight or obese are at risk of developing severe liver disease or liver cancer in later life, particularly those who have type 2 diabetes mellitus.
A novel calculator can more easily identify which esophageal adenocarcinoma patients derive an overall survival benefit from neoadjuvant chemoradiation to help guide treatment choices.
Some women with breast cancer may survive longer if they consume soy-based foods, according to a new study.
There is a critical need for new therapies for T-cell lymphomas, and with ongoing trials of mTOR and aurora kinase inhibitors, PI3K inhibitors, and others, new options may be on the horizon.
A handful of novel antibody-based therapies may soon emerge for the treatment of acute myeloid leukemia, according to a presentation at the 21st Annual International Congress on Hematologic Malignancies.